Latest Fund Strategy News

Zimi Limited posted 14% revenue growth and landed its biggest project order to date with Homecorp, while slashing operating costs and launching an AI sales agent.

Dimerix has completed adult patient recruitment in its Phase 3 ACTION3 trial for DMX-200, with a blinded review confirming the study remains statistically powered to demonstrate treatment efficacy. The company also appointed a new CFO and is negotiating up to US$50 million in non-dilutive funding.

Caravel Minerals has secured critical tenure and advanced engineering designs for its Caravel Copper Project, alongside non-binding debt interest of up to USD 220 million from European export credit agencies.

Meteoric Resources has reported strong pilot plant performance and advanced feasibility work at its Caldeira rare earths project, alongside a $50 million non-binding financing letter from Export Finance Australia and robust Brazilian government backing.

Celsius Resources appoints Bardin Davis as MD to lead financing efforts for the MCB Copper-Gold Project, extends Final Investment Decision timeline to late 2026, and navigates a complex ownership dispute in the Philippines while raising A$9.3 million.

Genesis Resources progresses environmental work at its Plavica project in North Macedonia while Australian field activities stall due to wet season, reporting a A$401k operating cash outflow and under two quarters of funding.

CurveBeam AI reported stable device orders but faces regulatory delays for FDA and China clearances, while securing a A$4 million investment from WEGO Orthopaedics and advancing clinical collaborations with robotic surgery systems.

Sky Metals has bolstered its cash reserves with a $20.5 million raise, backing a major drilling push at Tallebung and expanding exploration at Doradilla, positioning both projects for significant resource growth and development progress.

Argosy Minerals pushes forward its 12ktpa Rincon Lithium Project in Argentina, nearing DFS completion and securing a key 40MW energy infrastructure agreement amid robust lithium market demand.

Cambium Bio has clinched FDA agreement on a streamlined single pivotal Phase 3 trial for Elate Ocular®, cutting development complexity, while bolstering its cash position through a A$2.4 million strategic placement by major shareholder ZYBT.

Regener8 Resources has secured a binding agreement to acquire the Srebrenica North Project in Bosnia and Herzegovina, complemented by a successful $800,000 placement and a $2.87 million entitlement offer to fund exploration and due diligence.

NEXTDC has launched the retail tranche of its A$1.5 billion fully underwritten entitlement offer at A$12.70 per share, aiming to back accelerated data centre capacity growth amid unprecedented contracted utilisation.